Enlivex Therapeutics is trading 5.1% down today at $2.06 as the stock experiences sharp volatility following a massive analyst price target hike and significant equity dilution.
- H.C. Wainwright maintained a Buy rating with a significant $80 price target on August 3, 2026, triggering rapid investor repositioning.
- The stock remains under pressure following a July 28 filing detailing a highly dilutive $400 million private placement, which has fueled ongoing profit-taking and sell-side activity.